SOLENO THERAPEUTICS INC
SOLENO THERAPEUTICS INC (SLNO): 2 pipeline candidates · 1 upcoming catalyst · ~13 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
12.8 months
D/E 0.23 · 3% dilution
Lead: Approved
2 candidates
1 upcoming, next in ~3434d
0 buys · 6 sells (180d)
A transparent, data-derived signal for SOLENO THERAPEUTICS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2.8B
Cash
$133.0M
Quarterly Burn
$63.3M
Runway
12.8 mo
Revenue
$94.6M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (2 candidates)
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
224
Total value held
$2.08B
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 7,247,163 | $242.6M |
| fmr llc | 5,788,410 | $193.8M |
| wellington management group llp | 4,426,781 | $148.2M |
| vanguard capital management llc | 4,306,436 | $144.2M |
| blackrock, inc. | 3,742,774 | $125.3M |
| state street corp | 2,680,802 | $89.8M |
| woodline partners lp | 2,224,208 | $74.5M |
| polar capital holdings plc | 1,698,855 | $56.9M |
| caption management, llc | 1,589,343 | $53.2M |
| susquehanna international group, llp | 1,567,977 | $52.5M |
Showing top 10 of 224 institutional holders of SOLENO THERAPEUTICS INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in SOLENO THERAPEUTICS INC's pipeline?
SOLENO THERAPEUTICS INC (SLNO) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is SOLENO THERAPEUTICS INC's lead drug candidate?
SOLENO THERAPEUTICS INC's most advanced tracked candidate is dccr (BLA Filed) for Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia.
What is SOLENO THERAPEUTICS INC's next catalyst?
SOLENO THERAPEUTICS INC's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: VYKAT XR" — expected November 12, 2035.
What is SOLENO THERAPEUTICS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, SOLENO THERAPEUTICS INC has approximately 12.8 months of cash runway.
What is SOLENO THERAPEUTICS INC's market capitalization?
SOLENO THERAPEUTICS INC's market capitalization is approximately $2.8B.
Get the full picture on SOLENO THERAPEUTICS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.